Entera Bio Ltd (ENTX)

$2.38 0.00 (N/A)
Market Cap 109.14M
Revenue (ttm) 180,000.00
Net Income (ttm) -9.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,300.00%
Debt to Equity Ratio 0.00
Volume 39,200
Avg Vol 175,828
Day's Range N/A - N/A
Shares Out 45.86M
Stochastic %K 22%
Beta 1.67
Analysts Sell
Price Target $10.00

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 532 7151
Address:
Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel
TrevPhil13
TrevPhil13 Nov. 26 at 4:25 PM
$ENTX Hopefully announce phase 3 trial at meeting!
0 · Reply
WallStWireAds
WallStWireAds Nov. 18 at 1:03 PM
$ENTX https://caplynx.io/CLzbSfm
0 · Reply
d_risk
d_risk Nov. 14 at 10:34 PM
$ENTX - Entera Bio Ltd. Ordinary Shares - 10Q - Updated Risk Factors ENTX flags heightened risks from escalating Middle East conflicts—Israel-Hamas war, Iran/US airstrikes, ceasefire uncertainty, and Moody’s downgrade—warning of possible material impacts on operations, fundraising, and share price. #Biotechnology #MarketVolatility #CreditDowngrade #MiddleEastConflict #GeopoliticalRisk 🟢 Added 🟠 Removed https://d-risk.ai/ENTX/10-Q/2025-11-14
1 · Reply
WallStWireAds
WallStWireAds Nov. 14 at 9:08 PM
$ENTX https://caplynx.io/44BTekf
0 · Reply
tymtested
tymtested Nov. 8 at 3:33 AM
$ENTX Pfizer just paid $10B for Metsera obesity drug. C’mon ENTX/OPK!!
0 · Reply
Cache_Money
Cache_Money Nov. 7 at 5:14 AM
$ENTX sus AF
0 · Reply
WallStWireAds
WallStWireAds Nov. 4 at 7:13 PM
$ENTX
0 · Reply
Stringy51
Stringy51 Nov. 1 at 12:04 AM
$ENTX that’s a big drop aftermarket. I wonder if phase 3 is delayed. Haven’t seen a mention other than 2026 start.
1 · Reply
bioland
bioland Oct. 30 at 1:57 PM
$ENTX Being pumped for an offering
0 · Reply
signaljumper
signaljumper Oct. 29 at 7:19 PM
$ENTX a Close above 2.79 Open the 3$ + area
0 · Reply
Latest News on ENTX
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 11 days ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Oct 23, 2025, 8:50 AM EDT - 5 weeks ago

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Oct 16, 2025, 8:45 AM EDT - 6 weeks ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Entera Bio Beats Q2 EPS Estimates

Aug 8, 2025, 5:17 PM EDT - 4 months ago

Entera Bio Beats Q2 EPS Estimates

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Aug 8, 2025, 4:05 PM EDT - 4 months ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Jul 28, 2025, 7:30 AM EDT - 4 months ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

May 9, 2025, 4:05 PM EDT - 7 months ago

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Mar 28, 2025, 4:05 PM EDT - 8 months ago

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Mar 17, 2025, 8:00 AM EDT - 9 months ago

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 9 months ago

Entera Bio to Participate in Upcoming Events

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 27, 2025, 8:00 AM EST - 10 months ago

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Nov 8, 2024, 4:05 PM EST - 1 year ago

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 15, 2024, 8:00 AM EDT - 1 year ago

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 13, 2024, 7:00 AM EDT - 1 year ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 10, 2024, 4:10 PM EDT - 1 year ago

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 8, 2024, 4:05 PM EST - 1 year ago

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 4, 2024, 8:30 AM EST - 1 year ago

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 8:30 AM EST - 1 year ago

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Jan 3, 2024, 8:00 AM EST - 2 years ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Dec 26, 2023, 8:00 AM EST - 2 years ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 29, 2023, 8:30 AM EST - 2 years ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 14, 2023, 7:30 AM EST - 2 years ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Nov 9, 2023, 2:30 PM EST - 2 years ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 12, 2023, 8:30 AM EDT - 2 years ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 16, 2023, 8:30 AM EDT - 2 years ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Jun 7, 2023, 7:30 AM EDT - 2 years ago

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 5, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 3, 2023, 9:34 AM EDT - 2 years ago

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Apr 26, 2023, 8:30 AM EDT - 2 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Mar 31, 2023, 4:00 PM EDT - 2 years ago

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 2 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Feb 15, 2023, 10:00 AM EST - 3 years ago

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Feb 13, 2023, 9:00 AM EST - 3 years ago

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Nov 10, 2022, 4:15 PM EST - 3 years ago

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Oct 6, 2022, 7:00 AM EDT - 3 years ago

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 12, 2022, 4:30 PM EDT - 3 years ago

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Sep 12, 2022, 6:30 AM EDT - 3 years ago

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Aug 11, 2022, 6:30 AM EDT - 3 years ago

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Jul 26, 2022, 7:30 AM EDT - 3 years ago

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

TrevPhil13
TrevPhil13 Nov. 26 at 4:25 PM
$ENTX Hopefully announce phase 3 trial at meeting!
0 · Reply
WallStWireAds
WallStWireAds Nov. 18 at 1:03 PM
$ENTX https://caplynx.io/CLzbSfm
0 · Reply
d_risk
d_risk Nov. 14 at 10:34 PM
$ENTX - Entera Bio Ltd. Ordinary Shares - 10Q - Updated Risk Factors ENTX flags heightened risks from escalating Middle East conflicts—Israel-Hamas war, Iran/US airstrikes, ceasefire uncertainty, and Moody’s downgrade—warning of possible material impacts on operations, fundraising, and share price. #Biotechnology #MarketVolatility #CreditDowngrade #MiddleEastConflict #GeopoliticalRisk 🟢 Added 🟠 Removed https://d-risk.ai/ENTX/10-Q/2025-11-14
1 · Reply
WallStWireAds
WallStWireAds Nov. 14 at 9:08 PM
$ENTX https://caplynx.io/44BTekf
0 · Reply
tymtested
tymtested Nov. 8 at 3:33 AM
$ENTX Pfizer just paid $10B for Metsera obesity drug. C’mon ENTX/OPK!!
0 · Reply
Cache_Money
Cache_Money Nov. 7 at 5:14 AM
$ENTX sus AF
0 · Reply
WallStWireAds
WallStWireAds Nov. 4 at 7:13 PM
$ENTX
0 · Reply
Stringy51
Stringy51 Nov. 1 at 12:04 AM
$ENTX that’s a big drop aftermarket. I wonder if phase 3 is delayed. Haven’t seen a mention other than 2026 start.
1 · Reply
bioland
bioland Oct. 30 at 1:57 PM
$ENTX Being pumped for an offering
0 · Reply
signaljumper
signaljumper Oct. 29 at 7:19 PM
$ENTX a Close above 2.79 Open the 3$ + area
0 · Reply
Nader5444
Nader5444 Oct. 28 at 6:32 PM
$ENTX
0 · Reply
Stringy51
Stringy51 Oct. 28 at 2:52 PM
$ENTX https://www.linkedin.com/posts/pharmaverse-podcast_leadership-hiringtips-womeninleadership-activity-7378803474962063361-Tjx9?utm_medium=ios_app&rcm=ACoAAAr1XmMBPzloCRFlzmT6eeMwfl0wN-JDgu0&utm_source=social_share_send&utm_campaign=copy_link Interesting interview done recently. Hopefully that with good research we can keep this heading the right direction.
0 · Reply
Nader5444
Nader5444 Oct. 27 at 9:21 PM
$ENTX
0 · Reply
tymtested
tymtested Oct. 24 at 9:49 PM
$ENTX market only buys potential if its AI
0 · Reply
WallStWireAds
WallStWireAds Oct. 24 at 8:51 AM
$ENTX
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 23 at 3:07 PM
$ENTX just reversed 3% higher to -1% (~2Mv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
Butcher1871
Butcher1871 Oct. 23 at 2:30 PM
$ENTX thought this might move after hearing the news, whats the deal with this stock then long term holders?
2 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:34 PM
$ENTX 09:05 on Oct. 23 2025 Entera Bio Presents New Clinical Data From Phase 2 Study Of EB613 At 2025 North American Menopause Society Annual Meeting; Intends To Initiate Global Registrational Phase 3 Trial After July 2025 FDA Concurrence #tradeideas
0 · Reply
signaljumper
signaljumper Oct. 23 at 1:21 PM
$ENTX Grear News from Phase 2 https://www.globenewswire.com/news-release/2025/10/23/3172057/0/en/Entera-Bio-Presents-Positive-New-Clinical-Data-from-EB613-Phase-2-Trial-Demonstrating-Significant-Bone-Density-Improvements-in-Early-Postmenopausal-Women.html
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:15 PM
$ENTX 08:58 on Oct. 23 2025 Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause #tradeideas
0 · Reply
PennySpot
PennySpot Oct. 23 at 1:09 PM
ALERT ENTX · Score 95.2% | News: Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause --- https://news-static.webullfintech.com/us/news-html/20251023/13730920608436224.html | $2025-10-23 13:09:24 $$ENTX
0 · Reply
MHM7700
MHM7700 Oct. 23 at 12:58 PM
42% win on traded capital in less than 30 minutes on $ENTX, $MAIA and $INBS. That means if you invested 1,000 this morning, you would be walking off with more than 400 now as these trades were apart in time and you could use the same capital again and again. This is what we do everyday in our discord. This is what you get when you trade with real traders instead of FURUs here who just talk. I give clear trade alerts with PTs and SLs every time along with proof of me taking the same trade.
2 · Reply